Monoclonal antibodies for prophylactic and therapeutic use against viral infections()

Mostrar otras versiones (1)

Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be use...

Descripción completa

Detalles Bibliográficos
Autores principales: Both, Leonard, Banyard, Ashley C., van Dolleweerd, Craig, Wright, Edward, Ma, Julian K.-C., Fooks, Anthony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Urban & Partner Sp. z.o.o. 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111719/
https://www.ncbi.nlm.nih.gov/pubmed/32287402
http://dx.doi.org/10.1016/j.pepo.2013.08.006
_version_ 1783513338877050880
author Both, Leonard
Banyard, Ashley C.
van Dolleweerd, Craig
Wright, Edward
Ma, Julian K.-C.
Fooks, Anthony R.
author_facet Both, Leonard
Banyard, Ashley C.
van Dolleweerd, Craig
Wright, Edward
Ma, Julian K.-C.
Fooks, Anthony R.
author_sort Both, Leonard
collection PubMed
description Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable.
format Online
Article
Text
id pubmed-7111719
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Published by Elsevier Urban & Partner Sp. z.o.o.
record_format MEDLINE/PubMed
spelling pubmed-71117192020-04-02 Monoclonal antibodies for prophylactic and therapeutic use against viral infections() Both, Leonard Banyard, Ashley C. van Dolleweerd, Craig Wright, Edward Ma, Julian K.-C. Fooks, Anthony R. Pediatr Pol Article Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable. Published by Elsevier Urban & Partner Sp. z.o.o. 2013 2013-08-23 /pmc/articles/PMC7111719/ /pubmed/32287402 http://dx.doi.org/10.1016/j.pepo.2013.08.006 Text en Crown copyright © 2013 Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Both, Leonard
Banyard, Ashley C.
van Dolleweerd, Craig
Wright, Edward
Ma, Julian K.-C.
Fooks, Anthony R.
Monoclonal antibodies for prophylactic and therapeutic use against viral infections()
title Monoclonal antibodies for prophylactic and therapeutic use against viral infections()
title_full Monoclonal antibodies for prophylactic and therapeutic use against viral infections()
title_fullStr Monoclonal antibodies for prophylactic and therapeutic use against viral infections()
title_full_unstemmed Monoclonal antibodies for prophylactic and therapeutic use against viral infections()
title_short Monoclonal antibodies for prophylactic and therapeutic use against viral infections()
title_sort monoclonal antibodies for prophylactic and therapeutic use against viral infections()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111719/
https://www.ncbi.nlm.nih.gov/pubmed/32287402
http://dx.doi.org/10.1016/j.pepo.2013.08.006
work_keys_str_mv AT bothleonard monoclonalantibodiesforprophylacticandtherapeuticuseagainstviralinfections
AT banyardashleyc monoclonalantibodiesforprophylacticandtherapeuticuseagainstviralinfections
AT vandolleweerdcraig monoclonalantibodiesforprophylacticandtherapeuticuseagainstviralinfections
AT wrightedward monoclonalantibodiesforprophylacticandtherapeuticuseagainstviralinfections
AT majuliankc monoclonalantibodiesforprophylacticandtherapeuticuseagainstviralinfections
AT fooksanthonyr monoclonalantibodiesforprophylacticandtherapeuticuseagainstviralinfections

Ejemplares similares